Lakefront Biotherapeutics (LKFT) Finished Goods (2020 - 2023)

Lakefront Biotherapeutics (LKFT) has reported Finished Goods for 4 consecutive years, with $7.0 million the latest figure, recorded in Q4 2023.

• Quarterly Finished Goods fell 24.13% year-over-year to $7.0 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $7.0 million (down 24.13% YoY) and the FY2023 annual result came in at $7.0 million, down 24.13% from the prior year.
• Finished Goods fell to $7.0 million in Q4 2023 per LKFT's latest filing, from $9.2 million in the prior quarter.
• Over the last five years, Finished Goods for LKFT reached as high as $9.2 million in Q4 2022 and fell as low as $40966.4 in Q4 2020.
• A 4-year average of $5.4 million and a median of $6.2 million in 2021 frame the typical range for Finished Goods.
• Annual changes were most pronounced in 2021 — Finished Goods jumped 13350.0% — and 2023, when it declined 24.13%.
• Year by year, Finished Goods stood at $40966.4 in 2020, then soared by 13350.0% to $5.5 million in 2021, then surged by 66.52% to $9.2 million in 2022, then dropped by 24.13% to $7.0 million in 2023.
• According to Business Quant data, Finished Goods over the past three periods registered $7.0 million, $9.2 million, and $5.5 million for Q4 2023, Q4 2022, and Q4 2021 respectively.